Clinical Trial

A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who have not progressed after chemoradiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-20.
Trial Details
NCT Number NCT06469879
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Small Cell Lung Cancer Limited Stage
Enrollment 358 participants
Start Date 2024-09
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2024-07-01